CAH CARDINAL HEALTH INC
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 721371 · Fiscal year ends 06/30
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY14.2%
TTM net income YoY9.8%
TTM EPS YoY12.1%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR73.2%
Margins
Gross margin3.8%
Operating margin1.0%
Net margin0.7%
FCF margin1.8%
EBITDA margin1.4%
Returns
ROE—
ROA3.1%
ROIC (approx.)135.8%
Asset turnover4.61x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio0.88x
Interest coverage7.51x
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-6.3%
Payout ratio28.6%
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| Cost of revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B |
| Gross profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B |
| SG&A expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B |
| Operating income | $2.61B | $2.27B | $1.24B | $752.00M | -$607.00M |
| Interest expense | $348.00M | $215.00M | $51.00M | $84.00M | $147.00M |
| Pretax income | $2.17B | $2.10B | $1.20B | $663.00M | -$784.00M |
| Income tax | $469.00M | $532.00M | $348.00M | $332.00M | $153.00M |
| Net income | $1.71B | $1.56B | $852.00M | $330.00M | -$938.00M |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.44B | $85.00M |
| EPS (basic) | 7.27 | 6.48 | 3.48 | 1.27 | -3.37 |
| EPS (diluted) | 7.23 | 6.45 | 3.45 | 1.26 | -3.37 |
| Dividends declared per share | 2.04 | 2.02 | 2.00 | 1.98 | 1.96 |
| Weighted avg. shares (diluted) | 237.00M | 242.00M | 247.00M | 262.00M | 279.00M |
| Balance sheet | |||||
| Cash & equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.75B |
| Short-term investments | — | — | $200.00M | — | — |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B |
| Current assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B |
| PP&E, net | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B |
| Total assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B |
| Current liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B |
| Short-term debt | $1.88B | $550.00M | $434.00M | $792.00M | $580.00M |
| Long-term debt | $7.00B | $7.98B | $4.66B | $3.91B | $4.74B |
| Total debt | $8.89B | $8.53B | $5.09B | $4.70B | $5.32B |
| Total liabilities | $60.02B | $55.76B | $48.33B | $46.31B | $44.76B |
| Shareholders' equity | -$2.88B | -$2.78B | -$3.21B | -$2.96B | -$709.00M |
| Net debt | $4.03B | $4.65B | -$41.00M | $625.00M | $570.00M |
| Cash flow statement | |||||
| Operating cash flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B |
| Capital expenditure | $649.00M | $547.00M | $511.00M | $481.00M | $387.00M |
| Free cash flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.79B |
| Investing cash flow | -$2.58B | -$5.59B | -$1.85B | -$454.00M | $567.00M |
| Financing cash flow | -$1.60B | $1.94B | -$847.00M | -$3.05B | -$2.46B |
| Depreciation & amortization | $956.00M | $790.00M | $710.00M | $692.00M | $692.00M |
| Stock-based compensation | $367.00M | $244.00M | $121.00M | $96.00M | $81.00M |
| Dividends paid | $491.00M | $494.00M | $499.00M | $525.00M | $559.00M |
| Share buybacks | $1.36B | $765.00M | $750.00M | $2.00B | $1.00B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.